Chantal Tse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chantal Tse has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Didier Brault
Laboratoire de Biochimie
2 shared publicationsJacqueline Capeau
Laboratoire de Biochimie
2 shared publications- Anne-Sophie Gauchez
CHU Grenoble
1 shared publication Antoine Flahault
1 shared publicationGuillaume Lefevre
1 shared publicationJean-Pierre Lotz
Service d’Oncologie, and
1 shared publication
Latest Publications
- 1 April 2012
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (2) , 133-142
HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
- 1 April 2012
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (2) , 133-142
HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
- 1 July 2005
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (7) , 1093-1101
Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients
Background: HER-2 status is generally determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). Both methods are only semiquantitative, require a tumor sample, and can be difficult to reproduce. We compared these methods with 2 quantitative approaches, one measuring HER-2 gene copy number in tissue by real-time quantitative PCR (qPCR), and the other measuring shed HER-2 protein in serum by ELISA in patients with metastatic disease. Methods: We analyzed 52 cases of metastatic breast cancer for which both serum collected at the diagnosis of metastasis and stored primary breast tumor specimens were available. The within- and between-run imprecision of real-time qPCR and ELISA were evaluated according to Clinical and Laboratory Standards Institute (formerly known as NCCLS) recommendations. Concordance among the 4 methods was assessed by calculating the κ statistic and its 95% confidence interval (95% CI). Results: The CVs for within- and between-run imprecision were both Conclusions: Measurements of HER-2 gene expression by qPCR and of serum HER-2 protein by ELISA are highly reproducible approaches for determining HER-2 status in metastatic breast cancer. In addition, ELISA eliminates the need for biopsy.
- 1 July 2005
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (7) , 1093-1101
Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients
Background: HER-2 status is generally determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). Both methods are only semiquantitative, require a tumor sample, and can be difficult to reproduce. We compared these methods with 2 quantitative approaches, one measuring HER-2 gene copy number in tissue by real-time quantitative PCR (qPCR), and the other measuring shed HER-2 protein in serum by ELISA in patients with metastatic disease. Methods: We analyzed 52 cases of metastatic breast cancer for which both serum collected at the diagnosis of metastasis and stored primary breast tumor specimens were available. The within- and between-run imprecision of real-time qPCR and ELISA were evaluated according to Clinical and Laboratory Standards Institute (formerly known as NCCLS) recommendations. Concordance among the 4 methods was assessed by calculating the κ statistic and its 95% confidence interval (95% CI). Results: The CVs for within- and between-run imprecision were both Conclusions: Measurements of HER-2 gene expression by qPCR and of serum HER-2 protein by ELISA are highly reproducible approaches for determining HER-2 status in metastatic breast cancer. In addition, ELISA eliminates the need for biopsy.
- 18 January 2004
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 42 (2) , 142-6
Increased serum maternal levels of the HER2 oncoprotein p105 ectodomain in preeclampsia
HER2/ERBB2 protein is a 185 kDa transmembrane growth factor receptor whose extracellular domain, a 105 kDa fragment (p105), can be released from cell surfaces by proteolytic cleavage. The aim of our study was to compare serum p105 concentrations in normal and pathological pregnancies and to determine whether any correlation exists between preeclampsia and p105 levels. Serum p105 was assayed in 96 nonpregnant women and 89 pregnant women (26 normotensive, 14 normotensive with a history of preeclampsia or fetal hypotrophy, 10 with chronic hypertension, 10 with gestational hypertension and 29 with preeclampsia). Median serum p105 levels (median; 95% confidence interval) were higher in the preeclampsia group (13.9 μg/l; 12.8–16.1 μg/l) than in the normotensive (11.7 μg/l; 10.6μ13.3 μg/l; p<0.05) or non-pregnant groups (9.3 μg/l; 8.9–9.6 μg/l; p<0.001). There were no significant differences between the other pregnancy groups. In the normotensive group, serum p105 was correlated with the number of gestations (r=0.46; p<0.05), parity (r=0.39; p<0.05) and placenta weight (r=0.61; p<0.05). In preeclamptic women, serum p105 correlated with parity (r=0.46; p<0.05). Serum p105 concentrations above 11.9 μg/l were associated with a high odds ratio (OR) for onset of preeclampsia (after adjustment for parity OR=9.0; 95% CI=2.3–36.0; p<0.005). Preeclampsia is associated with increased serum p105 concentrations, which may be related to increased fetomaternal cell traffic.
- 18 January 2004
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 42 (2) , 142-6
Increased serum maternal levels of the HER2 oncoprotein p105 ectodomain in preeclampsia
HER2/ERBB2 protein is a 185 kDa transmembrane growth factor receptor whose extracellular domain, a 105 kDa fragment (p105), can be released from cell surfaces by proteolytic cleavage. The aim of our study was to compare serum p105 concentrations in normal and pathological pregnancies and to determine whether any correlation exists between preeclampsia and p105 levels. Serum p105 was assayed in 96 nonpregnant women and 89 pregnant women (26 normotensive, 14 normotensive with a history of preeclampsia or fetal hypotrophy, 10 with chronic hypertension, 10 with gestational hypertension and 29 with preeclampsia). Median serum p105 levels (median; 95% confidence interval) were higher in the preeclampsia group (13.9 μg/l; 12.8–16.1 μg/l) than in the normotensive (11.7 μg/l; 10.6μ13.3 μg/l; p<0.05) or non-pregnant groups (9.3 μg/l; 8.9–9.6 μg/l; p<0.001). There were no significant differences between the other pregnancy groups. In the normotensive group, serum p105 was correlated with the number of gestations (r=0.46; p<0.05), parity (r=0.39; p<0.05) and placenta weight (r=0.61; p<0.05). In preeclamptic women, serum p105 correlated with parity (r=0.46; p<0.05). Serum p105 concentrations above 11.9 μg/l were associated with a high odds ratio (OR) for onset of preeclampsia (after adjustment for parity OR=9.0; 95% CI=2.3–36.0; p<0.005). Preeclampsia is associated with increased serum p105 concentrations, which may be related to increased fetomaternal cell traffic.